Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
127005 trials found · Page 454 of 6351
-
New drug combo aims to boost stem cell transplant success in tough lymphoma
Disease control Recruiting nowThis phase I/II trial studies the side effects and best dose of pralatrexate in combination with bendamustine and total-body irradiation (TBI) followed by a donor stem cell transplant in treating patients with T-cell non-Hodgkin lymphoma that has come back after a period of impro…
Phase 1/2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Heart scan strategy aims to slash cardiac events in rural china
Prevention By invitation onlyThe CARDIAC trial is a prospective, parallel, open-label cluster randomized trial that aims to determine the effectiveness of a coronary computed tomography angiography (CTA)-guided intensive intervention strategy, as compared with standard care, on reducing the incidence of majo…
Sponsor: Harbin Medical University • Aim: Prevention
Last updated Jun 27, 2026 14:00 UTC
-
Double attack: surgery plus laser zaps deadly brain tumors
Disease control Recruiting nowButterfly glioblastomas (bGBM), defined as tumours crossing the midline to involve hemispheres bilaterally, have a dismal prognosis with a median survival of 3.3-6 months and only 9% of patients with bGBM survive 2-years. These figures put bGBM in the worst end of the spectrum of…
Sponsor: King's College Hospital NHS Trust • Aim: Disease control
Last updated Sep 05, 2026 00:00 UTC
-
Stem cell gel could speed burn healing in new trial
Disease control Recruiting nowBurn patients were randomly divided into the low-dose stem cell gel group, the high-dose stem cell gel group, and the placebo group (with only the gel), and received the same treatment under the same conditions simultaneously.
Sponsor: The First Affiliated Hospital of Xinxiang Medical College • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Artificial intelligence reads tissue samples in minutes to guide cancer surgery
Knowledge-focused OngoingThis multicenter observational study aims to develop and validate an artificial intelligence foundation model for frozen-section pathology. The study includes a retrospective phase and a prospective validation phase. Retrospective frozen-section pathology data will be used for m…
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC
-
Can AI read heart scans as well as experts?
Diagnosis Recruiting nowTransthoracic echocardiography is an essential imaging modality for the diagnosis and follow-up of cardiovascular diseases. Comprehensive echocardiographic assessment requires multiple quantitative measurements of cardiac structure and function, which are time-consuming and highl…
Sponsor: Centro Cardiologico Monzino • Aim: Diagnosis
Last updated Aug 02, 2026 00:00 UTC
-
New shot could help obese patients breathe better at night without CPAP
Disease control Not yet recruitingThis study is a multicenter, randomized, double-blind, parallel, placebo-controlled Phase III clinical trial evaluating the efficacy and safety of GZR18 injection in obese subjects with moderate to severe obstructive sleep apnea who are unable or unwilling to undergo positive air…
Phase 3 • Sponsor: Gan & Lee Pharmaceuticals. • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Can a new injection help tackle obesity? a trial puts MWN105 to the test
Disease control Recruiting nowThis study is a randomized, double-blind, placebo-controlled, multiple-dose, dose-escalation phase I clinical trial aiming to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity of MWN105 injection in Chinese non-diabetic overweight or obese …
Phase 1 • Sponsor: Shanghai Minwei Biotechnology Co., Ltd • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New stent combo could shorten blood thinner use for major heart artery blockage
Disease control Recruiting nowThe management of patients with unprotected left main coronary artery (LMCA) disease undergoing percutaneous coronary intervention (PCI) in contemporary interventional cardiology practice remains matter of intense debate. Particularly, the combination of the optimal drug-eluting …
Sponsor: IGLESIAS Juan Fernando • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Poop pills aim to break the cycle of recurrent c. diff
Disease control Recruiting nowDouble blind RCT study of tretment of recurrent Clostridioides difficile infection by FMT capsules.
Phase 3 • Sponsor: Helsinki University Central Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New hope for CML patients: asciminib combo trial launches
Disease control Not yet recruitingThis study is testing a new way to treat people with a type of blood cancer called chronic myeloid leukemia (CML) in chronic phase. This study is for the patients whose first treatment with a drug called a tyrosine kinase inhibitor (TKI; standard therapy) did not work well and r…
Phase 2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
New drug combo targets Hard-to-Treat breast cancer
Disease control Not yet recruitingThe study is being conducted to explore the reasonable dosage and evaluate the efficacy, safety and tolerability of HLX43 (Anti-PD-L1 ADC) as a monotherapy or in combination with immune checkpoint inhibitors in Subjects with locally advanced, recurrent or metastatic triple-negati…
Phase 2 • Sponsor: Shanghai Henlius Biotech • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New Antibody-Drug cocktail targets tough colorectal cancer
Disease control Recruiting nowThis is an open-label, multicenter Phase 2 clinical study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of JS212-based combination therapies in patients with metastatic colorectal cancer (mCRC). JS212 is a bispecific antibody-drug conj…
Phase 2 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
RNA vaccine trial offers new hope for recurrent brain cancer patients
Vaccine Recruiting nowThe primary objective will be to demonstrate the manufacturing feasibility and safety, and to determine the maximum tolerated dose (MTD) of RNA-LP vaccines in pediatric patients with recurrent/progressive Medulloblastoma (MB)
Phase 1 • Sponsor: University of Florida • Aim: Vaccine
Last updated Jul 01, 2026 00:00 UTC
-
Can a simple vancomycin taper beat a pricey drug for recurrent c. diff?
Prevention Recruiting nowIndirect evidence from network meta-analyses of randomized controlled trials (RCTs) suggest that a pulse and taper (P-T) of vancomycin may be non-inferior to 10-days of fidaxomicin for the prevention of recurrent Clostridioides difficile infections (rCDI). The aim of this trial i…
Phase 3 • Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre • Aim: Prevention
Last updated Jun 27, 2026 14:03 UTC
-
Heart artery showdown: which treatment wins for younger patients?
Disease control Recruiting nowThe goal of this study is to investigate the equivalence in early and long-term efficacy between the two "Leave nothing behind strategies" (Drug-Coated Baloon \[DCB\] strategy with bail-out BioResorbable Scaffold \[BRS\] versus BRS strategy) of de-novo native coronary artery lesi…
Sponsor: Ceric Sàrl • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
New hope for stomach cancer patients with abdominal spread: experimental drug combo enters trial
Disease control Recruiting nowThis study is a prospective, randomized, two-cohort trial designed to evaluate the efficacy and safety of two regimens in the treatment of gastric or gastroesophageal junction adenocarcinoma with peritoneal metastasis: SHR-1701 combined with intravenous and intraperitoneal paclit…
Phase 2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New combo therapy aims to halt ALK-Positive lung cancer
Disease control Recruiting nowThis is an open-label, multicenter, randomized phase 2 trial for patients with tyrosine kinase inhibitor-naïve ALKrearranged advanced NSCLC. Subjects are initially treated with lorlatinib for 12 weeks.
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New combo therapy aims to stop head and neck cancer from returning
Disease control Recruiting nowThis phase II trial tests the addition of chemotherapy, with carboplatin and paclitaxel, or chemo-immunotherapy, with carboplatin, paclitaxel and cemiplimab to standard salvage surgery followed by post operative radiation therapy and cisplatin for high risk patients, for the trea…
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 10, 2026 00:00 UTC
-
New shot could help eczema sufferers who Don't respond to steroids
Disease control Recruiting nowThe main aim of the study is to evaluate the efficacy, safety, and tolerability of lebrikizumab treatment in adult participants with Nummular Eczema (NE) who are not adequately controlled with Topical corticosteroids (TCS) or when this treatment is not medically advisable.
Phase 3 • Sponsor: Almirall, S.A. • Aim: Disease control
Last updated Aug 19, 2026 00:00 UTC